Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Asthma
Interventions
DRUG

Dupilumab

Solution for injection, one subcutaneous injection.

DRUG

Placebo (for Dupilumab)

Solution for injection, one subcutaneous injection.

DRUG

Fluticasone/Salmeterol combination therapy

Oral inhalation twice daily.

DRUG

Fluticasone monotherapy

Oral inhalation twice daily.

DRUG

Albuterol

Oral inhalation as needed.

DRUG

Levalbuterol

Oral inhalation as needed.

Trial Locations (50)

15213

Investigational Site Number 840037, Pittsburgh

17033

Investigational Site Number 840040, Hershey

19013

Investigational Site Number 840009, Upland

21287

Investigational Site Number 840014, Baltimore

23229

Investigational Site Number 840049, Richmond

27103

Investigational Site Number 840008, Papillion

29407

Investigational Site Number 840027, Charleston

32308

Investigational Site Number 840044, Tallahassee

33612

Investigational Site Number 840029, Tampa

42303

Investigational Site Number 840053, Owensboro

43560

Investigational Site Number 840023, Sylvania

46208

Investigational Site Number 840028, Indianapolis

52240

Investigational Site Number 840038, Iowa City

53792

Investigational Site Number 840034, Madison

55402

Investigational Site Number 840003, Minneapolis

Investigational Site Number 840010, Minneapolis

59718

Investigational Site Number 840022, Bozeman

63110

Investigational Site Number 840006, St Louis

63141

Investigational Site Number 840013, St Louis

66210

Investigational Site Number 840021, Overland Park

68131

Investigational Site Number 840025, Omaha

73120

Investigational Site Number 840045, Oklahoma City

78229

Investigational Site Number 840050, San Antonio

79902

Investigational Site Number 840030, El Paso

80206

Investigational Site Number 840011, Denver

80230

Investigational Site Number 840017, Denver

80907

Investigational Site Number 840031, Colorado Springs

90025

Investigational Site Number 840032, Los Angeles

90048

Investigational Site Number 840036, Los Angeles

90274

Investigational Site Number 840035, Rolling Hills Estates

90806

Investigational Site Number 840046, Long Beach

92506

Investigational Site Number 840048, Riverside

92691

Investigational Site Number 840005, Mission Viejo

92804

Investigational Site Number 840047, Anaheim

92868

Investigational Site Number 840007, Orange

94143

Investigational Site Number 840041, San Francisco

Investigational Site Number 840042, San Francisco

95117

Investigational Site Number 840039, San Jose

95207

Investigational Site Number 840002, Stockton

95405

Investigational Site Number 840024, Santa Rosa

97035

Investigational Site Number 840001, Lake Oswego

97209

Investigational Site Number 840016, Portland

97504

Investigational Site Number 840012, Medford

98105

Investigational Site Number 840020, Seattle

06510

Investigational Site Number 840026, New Haven

02747

Investigational Site Number 840015, North Dartmouth

08540

Investigational Site Number 840018, Princeton

27157-1071

Investigational Site Number 840004, Winston-Salem

05403

Investigational Site Number 840052, South Burlington

98415-0299

Investigational Site Number 840019, Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY